Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas clinical trial (NCT06350318). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas clinical trial (NCT06350318). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the side effects I might experience from zanubrutinib and rituximab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas clinical trial (NCT06350318). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas clinical trial (NCT06350318). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas clinical trial (NCT06350318). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any specific eligibility requirements I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas clinical trial (NCT06350318). Contact the study team or your healthcare provider for specific answers.

What this study is about